Our group has previously adopted single-cell sequencing to analyze the characteristics of tumor neoantigen-specific T cell subsets and evaluated the correlation between the tumor neoantigen-specific T cells and PD-1 inhibitor immunotherapy response [98]. This evidence concerns the gene PDCD1 and neoplasm.